Objective: To assess real-life treatment practices with imatinib for chronic-phase chronic
myeloid leukaemia (CP-CML) in France. Research design and methods: In the …

Data are limited in developing countries regarding the clinicopathologic features and
response to therapy of chronic myeloid leukemia (CML) in the era of imatinib (IM). The …

Purpose Little is known about the actual management and treatment of chronic myeloid
leukemia (CML) in clinical practice, although there have been many recent changes, such …

Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib
were obtained from clinical trials that may differ from the routine practice. We report the …

Abstract The European LeukemiaNet recently published recommendations for evaluating
response to imatinib among pts with CML. Criteria for failure and suboptimal responses …

Imatinib (IM) at 400 mg daily is the first line therapy for newly diagnosed CML patients (pts);
however, less than 50% of major molecular responses (MMR) are obtained at 12 months. To …

Here we compare the management and survival outcomes of chronic myeloid leukemia
(CML) patients who had early or late imatinib mesylate (IM) therapy. The cytogenetic and …

Imatinib (IM) at 400 mg daily has emerged as the preferred therapy for newly diagnosed
CML pts. Despite impressive results, only a minority of pts treated with IM achieved a …

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a
BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid …

Background Imatinib was the first tyrosine kinase inhibitor that has revolutionized the
therapy of chronic myeloid leukemia. It binds breakpoint cluster region–Abelson kinase …